CJC-1295 Manufacturing, Supply & Shortage History

How CJC-1295 Works: Mechanism of Action

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that binds the GHRH receptor on anterior pituitary somatotroph cells, triggering pulsatile growth hormone (GH) release. The peptide's 30-amino-acid sequence is based on the first 29 residues of endogenous GHRH (GRF 1-29) with four amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage 1.

The DAC Modification

The drug-affinity complex (DAC) variant adds a maleimidopropionic acid linker that binds covalently to serum albumin after injection. This albumin conjugation extends the circulating half-life from roughly 30 minutes (native GRF 1-29) to approximately 8 days 1. In the Teichman et al. Pharmacokinetic study (N=21 healthy males, ages 21 to 40), a single 60 mcg/kg subcutaneous dose of CJC-1295 DAC produced sustained mean GH levels 2- to 10-fold above baseline for 6 days, with IGF-1 elevations persisting through day 8 to 14 1.

Non-DAC (Mod GRF 1-29) Variant

The non-DAC form, commonly called mod GRF 1-29, retains the same four amino acid substitutions but omits the albumin-binding linker. Its half-life is roughly 30 minutes, producing a shorter, more physiologic GH pulse 2. This version requires daily or twice-daily dosing. Both variants act exclusively through the endogenous GHRH receptor pathway, preserving normal negative feedback from somatostatin and IGF-1, which distinguishes them from direct GH administration 3.

Peptide Synthesis: How CJC-1295 Is Manufactured

No FDA-approved commercial manufacturer produces CJC-1295. All supply depends on compounding pharmacies sourcing bulk peptide active pharmaceutical ingredient (API) synthesized through solid-phase peptide synthesis (SPPS) 4.

Solid-Phase Peptide Synthesis (SPPS)

SPPS, originally developed by Merrifield and refined over decades, builds the 30-amino-acid chain on a resin support one residue at a time using Fmoc (fluorenylmethyloxycarbonyl) chemistry 4. Each coupling cycle involves deprotection, activation, and amide bond formation. For CJC-1295, the four non-native amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) require specific protected building blocks to achieve correct incorporation 5.

After chain assembly, the peptide is cleaved from the resin, purified by reverse-phase HPLC, and lyophilized into a powder. The DAC variant requires an additional conjugation step: attaching the maleimidopropionic acid moiety to a lysine residue so the peptide can form its albumin bond in vivo. Typical batch yields for research-grade 30-mer peptides run 60% to 75% crude purity, with HPLC polishing raising final purity above 98% 4.

Raw Material Sourcing

Most bulk CJC-1295 API enters the U.S. Supply chain from contract peptide synthesis facilities. The FDA does not maintain an approved supplier list for compounding bulk substances the way it does for finished drug products. Instead, 503A pharmacies must source from suppliers that meet USP chapter 795/797 standards, and 503B outsourcing facilities must comply with current good manufacturing practice (cGMP) requirements under section 503B of the Federal Food, Drug, and Cosmetic Act 6.

Regulatory History and FDA Oversight

CJC-1295 has never completed a New Drug Application (NDA) or received FDA approval for any indication. Its availability in the U.S. Depends entirely on the compounding exemptions in sections 503A and 503B of the FD&C Act 7.

The 503A and 503B Framework

Under section 503A, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription, provided the bulk substance either appears on an FDA-approved drug product or is listed on the FDA's bulk drug substances list for pharmacy compounding 6. Section 503B outsourcing facilities may produce compounded drugs without patient-specific prescriptions but must register with the FDA, report adverse events, and follow cGMP 8.

CJC-1295 is not a component of any FDA-approved drug. Its compounding legality has rested on its nomination to the FDA's bulk drug substances evaluation list and on individual state pharmacy board interpretations 6.

FDA Warning Letters and Enforcement Actions

Between 2019 and 2023, the FDA issued a series of warning letters to compounding pharmacies producing injectable peptides including CJC-1295. Common violations cited in these letters included failure to follow cGMP, inadequate sterility assurance, stability testing deficiencies, and marketing of compounded products as alternatives to FDA-approved drugs 9. Several facilities received Form 483 observations for particulate contamination, endotoxin testing gaps, and insufficient environmental monitoring in their clean rooms 9.

The New England Compounding Center (NECC) meningitis outbreak of 2012, though unrelated to peptides, triggered passage of the Drug Quality and Security Act (DQSA) in 2013, fundamentally reshaping compounding oversight and establishing the 503B outsourcing facility category 10. The downstream effects of DQSA tightened scrutiny on all compounded injectables, peptides included.

Supply Chain Vulnerabilities

The CJC-1295 supply chain contains multiple chokepoints that have caused repeated availability disruptions for patients who depend on compounded peptide therapy.

API Import Restrictions

A significant share of bulk peptide API used by U.S. Compounders is synthesized overseas. FDA import alerts and detentions have periodically blocked shipments of peptide raw materials at ports of entry, particularly when certificates of analysis (COAs) fail to meet FDA expectations or when suppliers lack Drug Master File (DMF) registrations 11. In 2020 and 2021, pandemic-related shipping delays compounded these import holds, creating multi-month gaps in raw CJC-1295 availability at several major compounding operations 12.

State-Level Regulatory Variation

Compounding pharmacy regulations differ by state. Some state pharmacy boards have specifically restricted or banned compounding of research peptides that lack FDA-approved reference listed drugs. This patchwork creates geographic supply deserts where patients in one state can fill a CJC-1295 prescription while patients across the border cannot 8. The National Association of Boards of Pharmacy (NABP) has periodically flagged peptide compounders for non-compliance, further narrowing the active supplier base 13.

The 2023 Peptide Regulatory Shift

In late 2023, the FDA revisited its category 2 bulk drug substances list nominations and signaled that several peptides, including certain growth-hormone-releasing analogs, might not meet the safety and efficacy criteria for continued compounding eligibility 6. This review created anticipatory supply tightening as compounders reduced production volumes pending final FDA determinations. Patients reported wait times stretching from 1 to 2 weeks to 6 to 8 weeks at some pharmacies during this period.

Shortage Timeline: Key Events

The availability of CJC-1295 has fluctuated across several distinct periods. The table below summarizes the primary disruption events.

| Period | Event | Supply Impact | |---|---|---| | 2013 | DQSA passage creates 503B category | Increased compliance costs reduce number of compounders | | 2017 to 2018 | FDA bulk drug substance list reviews begin | Uncertainty slows new compounder entry | | 2019 to 2020 | Warning letters to multiple peptide compounders | Several facilities pause or cease peptide production | | 2020 to 2021 | COVID-19 pandemic disrupts API imports | 2- to 4-month raw material delays reported | | 2022 | Increased 503B inspections post-pandemic | Additional facilities fail cGMP inspection | | 2023 | FDA category 2 peptide list review announced | Anticipatory production cuts; patient wait times increase | | 2024 to 2025 | Ongoing regulatory uncertainty | Supply remains pharmacy- and state-dependent |

Each of these events narrowed the active supplier base. The cumulative effect has been a market where CJC-1295 availability depends heavily on which compounding pharmacies maintain both FDA/state compliance and reliable API sourcing 9.

Quality and Purity Concerns in Compounded CJC-1295

Because CJC-1295 lacks an FDA-approved reference standard, quality varies across compounding sources. Third-party analytical testing has identified several recurring issues.

Potency Variation

Independent assays of compounded CJC-1295 vials have shown potency ranges from 85% to 115% of label claim across different pharmacies. USP chapter 797 permits a potency range of 90% to 110% for compounded sterile preparations 14. Vials falling outside this range represent a clinical concern: underdosed product fails to produce therapeutic GH elevation, while overdosed product risks side effects including water retention, joint stiffness, and carpal tunnel-like symptoms 1.

Sterility and Endotoxin Testing

Injectable peptides must meet rigorous sterility and endotoxin limits. The FDA's inspection findings at peptide compounding facilities have repeatedly cited inadequate media fill testing, environmental monitoring failures, and endotoxin results that approached or exceeded the 5 EU/kg/hour pyrogenic threshold 9. A contaminated sterile injectable can cause local injection site infections, systemic bacteremia, or pyrogenic reactions 10.

Peptide Degradation

CJC-1295, like most peptides, is susceptible to oxidation, deamidation, and aggregation during storage. Proper lyophilization, cold-chain shipping (2 to 8°C), and reconstitution with bacteriostatic water are necessary to maintain stability. The Teichman et al. Study used material manufactured under GMP-equivalent research conditions with defined stability profiles 1. Not all compounding pharmacies replicate these storage and handling standards, and the FDA has noted stability testing deficiencies in inspection reports 9.

Clinical Evidence Base and Its Limits

The published evidence for CJC-1295 remains thin relative to FDA-approved growth hormone products.

Teichman et al. 2006: The Foundational Study

The most widely cited trial enrolled 21 healthy men aged 21 to 40 in a dose-escalation design testing single and multiple subcutaneous doses of CJC-1295 DAC (30, 60, and 125 mcg/kg). Mean GH area under the curve (AUC) increased 2- to 10-fold, and IGF-1 rose 1.5- to 3-fold above baseline, with effects sustained for 6 to 14 days after a single injection 1. Adverse events were mild: injection-site reactions, transient flushing, and headache. No serious adverse events occurred.

This remains a phase I/II pharmacokinetic study. It was not designed to evaluate clinical endpoints like body composition, bone density, or functional outcomes 1.

Broader GHRH Analog Literature

Sermorelin, another GHRH analog, received FDA approval in 1997 for diagnostic use and was studied for GH deficiency treatment before its manufacturer voluntarily discontinued it in 2008 due to commercial reasons, not safety signals 15. Tesamorelin (Egrifta), a GHRH analog approved for HIV-associated lipodystrophy, provides the closest regulatory precedent for the GHRH-receptor agonist class, demonstrating that sustained GHRH-receptor stimulation can reduce visceral adipose tissue in a defined population 16.

CJC-1295 has not replicated tesamorelin's regulatory pathway. No phase III trial has been completed, and no NDA has been filed 6.

What Patients Should Know About Current Availability

Accessing CJC-1295 in 2026 requires navigating a regulatory environment that changes faster than most patients expect. A practical decision framework:

1. Verify the pharmacy's registration. Confirm your compounding pharmacy is either a licensed 503A pharmacy in your state or a registered 503B outsourcing facility listed on the FDA's outsourcing facility database 8.

2. Request a certificate of analysis. A reputable compounder will provide a COA for each batch showing peptide identity (mass spectrometry), purity (HPLC, target ≥98%), endotoxin levels, and sterility test results.

3. Check state-level rules. Contact your state board of pharmacy to confirm CJC-1295 compounding is permitted. Rules have changed in multiple states between 2023 and 2025 13.

4. Expect supply variability. Even compliant pharmacies may experience 2- to 6-week lead times depending on API availability. Patients on stable therapy should discuss buffer prescriptions with their prescriber.

5. Monitor FDA announcements. The FDA's compounding page posts updates on bulk substance evaluations that directly affect CJC-1295 supply 6.

Prescribers ordering CJC-1295 should document the clinical rationale (e.g., adult GH deficiency confirmed by provocative testing with peak GH <5 mcg/L per Endocrine Society guidelines) and maintain baseline and follow-up IGF-1 monitoring every 4 to 8 weeks during dose titration 17.